SUPERMX 7106 QUARTERLY REPORT 30 JUN 2017
Quarterly Report Review:
这季的收入来自于整修工作后所产生的产量较高。
该集团在隐形眼镜的业务上花费了大量的广告费并且该集团认为在未来的12个月里隐形眼镜业务的开销还会持续下去以便将来隐形眼镜的业务能得到更大的市场。
该集团认为全球对手套的需求还是很高特别是医疗领域。
该集团也会持续整修，重建和改造旧工厂以提高生产量。
该集团在开发隐形眼镜业务方面取得良好进展。 不仅成功建立了生产经营，而且还在努力的让隐形眼镜产品得到认证和批准，并将其产品推向市场。
隐形眼镜产品获得的认证和批准包括美国FDA 510K，CE标志和巴西Anvisa牌照的超市; 和马来西亚市场的医疗器械管理局许可证。
该集团目前正在追求获得进入日本市场的认证，日本是第二大隐形眼镜市场。
该集团在获得必要的批准后，将继续在海外市场上推出产品。
Reference Price:
29.08.2017
Price: RM1.83
Rolling EPS: RM0.1044
PE: 17.53
NTA: RM1.57
Price/NTA: 1.17
PE*Price/NTA: 20.43
Undervalued: RM1.44
Fair Value: RM1.92
Overvalued: RM2.88
Disclaimer:
The information contained in this research is based on data obtained from sources believed to be reliable. However, the data and/or sources have not been independently verified and as such, no representation, express or implied, is made as to the accuracy, adequacy, completeness or reliability of the info or opinions in the research.
Accordingly, neither 以牛攻熊 nor any of its related companies and associates nor person connected to it accept any liability whatsoever for any direct, indirect or consequential losses (including loss of profits) or damages that may arise from the use or reliance on the info or opinions in this publication. Any information, opinions or recommendations contained herein are subject to change at any time without prior notice. 以牛攻熊 has no obligation to update its opinion or the information in this research.
Investors are advised to make their own independent evaluation of the info contained in this research and seek independent financial, legal or other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this research. Nothing in this research constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise represent a personal recommendation to you.
This research is being supplied to you on a strictly confidential basis solely for your information and is made strictly on the basis that it will remain confidential. All materials presented in this research, unless specifically indicated otherwise, is under copyright to 以牛攻熊. This research and its contents may not be reproduced, stored in a retrieval system, redistributed, transmitted or passed on, directly or indirectly, to any person or published in whole or in part, or altered in any way, for any purpose.
This research may provide the addresses of, or contain hyperlinks to, websites. 以牛攻熊 takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to 以牛攻熊 own site material) are provided solely for your convenience. The information and the content of the linked site do not in any way form part of this research. Accessing such website or following such link through the research or 以牛攻熊 site shall be at your own risk.
这季的收入来自于整修工作后所产生的产量较高。
该集团在隐形眼镜的业务上花费了大量的广告费并且该集团认为在未来的12个月里隐形眼镜业务的开销还会持续下去以便将来隐形眼镜的业务能得到更大的市场。
该集团认为全球对手套的需求还是很高特别是医疗领域。
该集团也会持续整修，重建和改造旧工厂以提高生产量。
该集团在开发隐形眼镜业务方面取得良好进展。 不仅成功建立了生产经营，而且还在努力的让隐形眼镜产品得到认证和批准，并将其产品推向市场。
隐形眼镜产品获得的认证和批准包括美国FDA 510K，CE标志和巴西Anvisa牌照的超市; 和马来西亚市场的医疗器械管理局许可证。
该集团目前正在追求获得进入日本市场的认证，日本是第二大隐形眼镜市场。
该集团在获得必要的批准后，将继续在海外市场上推出产品。
Reference Price:
29.08.2017
Price: RM1.83
Rolling EPS: RM0.1044
PE: 17.53
NTA: RM1.57
Price/NTA: 1.17
PE*Price/NTA: 20.43
Undervalued: RM1.44
Fair Value: RM1.92
Overvalued: RM2.88
Disclaimer:
The information contained in this research is based on data obtained from sources believed to be reliable. However, the data and/or sources have not been independently verified and as such, no representation, express or implied, is made as to the accuracy, adequacy, completeness or reliability of the info or opinions in the research.
Accordingly, neither 以牛攻熊 nor any of its related companies and associates nor person connected to it accept any liability whatsoever for any direct, indirect or consequential losses (including loss of profits) or damages that may arise from the use or reliance on the info or opinions in this publication. Any information, opinions or recommendations contained herein are subject to change at any time without prior notice. 以牛攻熊 has no obligation to update its opinion or the information in this research.
Investors are advised to make their own independent evaluation of the info contained in this research and seek independent financial, legal or other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this research. Nothing in this research constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise represent a personal recommendation to you.
This research is being supplied to you on a strictly confidential basis solely for your information and is made strictly on the basis that it will remain confidential. All materials presented in this research, unless specifically indicated otherwise, is under copyright to 以牛攻熊. This research and its contents may not be reproduced, stored in a retrieval system, redistributed, transmitted or passed on, directly or indirectly, to any person or published in whole or in part, or altered in any way, for any purpose.
This research may provide the addresses of, or contain hyperlinks to, websites. 以牛攻熊 takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to 以牛攻熊 own site material) are provided solely for your convenience. The information and the content of the linked site do not in any way form part of this research. Accessing such website or following such link through the research or 以牛攻熊 site shall be at your own risk.
Comments
Post a Comment